Amgen partners to launch biosimilars in China

artistic rendering of an anitbody molecule

Source: Shutterstock

US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology

The US biopharmaceutical firm Amgen and Chinese generic drug maker Simcere Pharmaceutical plan to co-develop and commercialise four biosimilars in China.

Amgen will be responsible for co-development, marketing approval applications and manufacturing of the biosimilars, while Simcere will be in charge of distribution and commercialisation activities in China.